Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy

Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta-like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in ex...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2024-12
Main Authors: Nam, Hohyung, Jung, Soon-Hee, Lee, Jii Bum, Kong, Jee Hyun, Lim, Seungtaek
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta-like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first-line chemotherapy. A total of 54 patients with extensive stage of SCLC (ES-SCLC) who were treated with first-line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno-histochemical staining for DLL3, and their clinico-pathologic data, including progression-free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells ≧ 75% and
ISSN:1759-7706
1759-7714
1759-7714
DOI:10.1111/1759-7714.15522